Dual MET/EGFR therapy leads to complete response and resistance prevention in a MET-amplified gastroesophageal xenopatient cohort
Sign Up to like & getrecommendations! Published in 2017 at "Oncogene"
DOI: 10.1038/onc.2016.283
Abstract: Amplification of the MET oncogene occurs in 2–4% of gastroesophageal cancers and defines a small and aggressive subset of tumors. Although in vitro studies have given very promising results, clinical trials with MET inhibitors have… read more here.
Keywords: met egfr; egfr therapy; resistance; dual met ... See more keywords
Met inhibition revokes IFNγ-induction of PD-1 ligands in MET-amplified tumours
Sign Up to like & getrecommendations! Published in 2019 at "British Journal of Cancer"
DOI: 10.1038/s41416-018-0315-3
Abstract: BackgroundInterferon-induced expression of programmed cell death ligands (PD-L1/PD-L2) may sustain tumour immune-evasion. Patients featuring MET amplification, a genetic lesion driving transformation, may benefit from anti-MET treatment. We explored if MET-targeted therapy interferes with Interferon-γ modulation… read more here.
Keywords: treatment; interferon; amplified tumours; induction ligands ... See more keywords
Characterization of Bozitinib as a potential therapeutic agent for MET-amplified gastric cancer
Sign Up to like & getrecommendations! Published in 2025 at "Communications Biology"
DOI: 10.1038/s42003-025-07490-5
Abstract: Hyperactive c-Met signaling pathway caused by altered MET is a common mechanism underlying gastric cancer and represents an attractive target for the treatment of gastric cancer with MET alterations. However, no c-Met kinase inhibitors are… read more here.
Keywords: cancer; met amplified; amplified gastric; gastric cancer ... See more keywords
Abstract CT251: Savolitinib (savo) + osimertinib (osi) vs savo + placebo (PBO) in patients (pts) with EGFR-mutated (EGFRm), MET-amplified advanced NSCLC with progression on osi
Sign Up to like & getrecommendations! Published in 2024 at "Cancer Research"
DOI: 10.1158/1538-7445.am2024-ct251
Abstract: Background Osi, an EGFR-TKI, is the preferred 1L treatment (tx) for EGFRm aNSCLC; however, resistance eventually develops in most pts. MET amplification is the most common known resistance mechanism to osi. Combining osi with savo,… read more here.
Keywords: osi savo; met amplified; progression; savo ... See more keywords
Targeting the tumor-promoting microenvironment in MET-amplified NSCLC cells with a novel inhibitor of pro-HGF activation
Sign Up to like & getrecommendations! Published in 2017 at "Oncotarget"
DOI: 10.18632/oncotarget.18260
Abstract: Targeted therapeutic agents, such as inhibitors of epithelial growth factor receptor (EGFR), have transformed the management of non-small cell lung cancer (NSCLC) patients. MET-amplified NSCLC cells display resistance to EGFR-targeting agents, but are addicted to… read more here.
Keywords: inhibitor pro; pro hgf; nsclc cells; amplified nsclc ... See more keywords
Phase I dose-escalation study of the c-Met tyrosine kinase inhibitor SAR125844 in Asian patients with advanced solid tumors, including patients with MET-amplified gastric cancer
Sign Up to like & getrecommendations! Published in 2017 at "Oncotarget"
DOI: 10.18632/oncotarget.18554
Abstract: SAR125844 is a potent and selective inhibitor of the c-Met kinase receptor. This was an open-label, phase I, multicenter, dose-escalation, and dose-expansion trial of SAR125844 in Asian patients with solid tumors, a subgroup of whom… read more here.
Keywords: dose escalation; gastric cancer; cancer; patients met ... See more keywords
Case Report: A rare case of MET-amplified gastric cancer with systemic metastasis: remarkable efficacy of crizotinib and the role of precision medicine
Sign Up to like & getrecommendations! Published in 2025 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2025.1555801
Abstract: Gastric cancer remains one of the most prevalent gastrointestinal malignancies, with certain subtypes, such as poorly cohesive carcinoma—including signet ring cell carcinoma (SRCC)—exhibiting aggressive progression and poor prognosis. Mesenchymal epithelial transition (MET) amplification, a relatively… read more here.
Keywords: cancer; met amplified; gastric cancer; efficacy ... See more keywords
Characterization of MET Alterations in 37 Gastroesophageal Cancer Cell Lines for MET-Targeted Therapy
Sign Up to like & getrecommendations! Published in 2024 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms25115975
Abstract: Capmatinib and savolitinib, selective MET inhibitors, are widely used to treat various MET-positive cancers. In this study, we aimed to determine the effects of these inhibitors on MET-amplified gastric cancer (GC) cells. Methods: After screening… read more here.
Keywords: cancer; met amplified; cell lines; cell ... See more keywords